The levels of serum Gas6 in patients with aGVHD or engraftment syndrome after HSCT. (A) The levels of serum Gas6 in patients within 6 weeks after HSCT were quantified by a human Gas6 ELISA kit. Data are expressed as mean ± SD (n = 14). *P < .05. (B) The levels of serum Gas6 were quantified by a human Gas6 ELISA kit in patients with grade 0 to I aGVHD (n = 7) and grade II-IV aGVHD (n = 7). Data are expressed as mean ± SD. *P < .05. (C) The levels of serum Gas6 in the patients with ES (n = 6) were significantly increased in comparison with those without ES (n = 8), using a human Gas6 ELISA kit. Data are expressed as mean ± SD. *P < .05. (Da-c) Gas6 protein was examined on the surface of CD3-positive lymphocytes, CD14-positive monocytes, and CD19-positive lymphocytes in the peripheral blood mononuclear cells of the patients without aGVHD, using flow cytometry data analysis. Representative data are from 3 independent experiments. (Ea-c) Our flow cytometry data analysis shows that Gas6 protein was examined on the surface of CD3-positive lymphocytes, CD14-positive monocytes, and CD19-positive lymphocytes in peripheral blood mononuclear cells of patients with aGVHD. Representative data are from 3 independent experiments. (Fa-d) LDH, creatinine levels, resistance to platelet transfusion, and thrombin-antithrombin complex values were significantly increased in the patients with grade II to IV aGVHD (n = 7) compared with those with grade 0 to I aGVHD (n = 7) at 3, 4, and 5 weeks after HSCT. Data are expressed as mean ± SD. *P < .05. (G) The levels of serum Gas6 correlated with blood LDH, d-dimer, and plasmin-alpha2 plasmin inhibitor complex (PIC) values in 3 representative cases with grade II to III aGVHD after HSCT.